Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2021-11-08 Major Shareholding Noti…
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding quantity and resulting percentage for a specific holder ('FLERIE INVEST AB') in the issuer ('XSpray Pharma AB (publ)'). It explicitly shows the 'Before the transaction' and 'After the transaction' holdings, including the number of shares and voting rights, crossing a threshold (implied by the 5% limit mention). This type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category. The document structure, focusing on share quantities and percentages after a transaction, matches the definition for Major Shareholding Notification (MRQ). It is not an earnings release (ER), a full annual report (10-K), or a director's dealing (DIRS), as it concerns a major shareholder, not necessarily a director's personal trade.
2021-11-08 English
Xspray Pharma completes a directed new share issue to Flerie Invest, raising approximately SEK 100 million
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a directed new share issue by Xspray Pharma AB to raise capital. It details the number of shares issued, the price per share, the rationale for the capital raise, and the impact on share capital and dilution. This falls under the category of 'Share Issue/Capital Change' (SHA) as it describes a specific corporate action regarding the issuance of new shares to raise funds.
2021-11-08 English
Xspray Pharma genomför en riktad nyemission till Flerie Invest och tillförs cirka 100 miljoner kronor
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that Xspray Pharma's board has decided on a directed new share issue (nyemission) to raise approximately 100 million SEK from Flerie Invest. This action directly relates to fundraising, capital structure changes, and the issuance of new shares. This fits the definition of 'Capital/Financing Update' (CAP) or 'Share Issue/Capital Change' (SHA). Since the core event is the decision to issue new shares to raise capital, 'Capital/Financing Update' (CAP) is highly appropriate, as is 'Share Issue/Capital Change' (SHA). Given the explicit mention of 'nyemission' (new issue) and the capital raised, SHA is the most precise fit for the action taken, although CAP is also relevant. I will select SHA as it describes the mechanism (share issue) used for the financing. The document is a formal announcement of this corporate action.
2021-11-08 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the third quarter of 2021 for Xspray Pharma AB. It contains comprehensive financial data, including income statements, cash flow statements, and management commentary on business performance and future outlook. It is not an announcement of a report, but the report itself, containing substantive financial analysis and data for a period shorter than a full fiscal year. 9M 2021
2021-10-26 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT THIRD QUARTER 2021' and contains detailed financial statements, management commentary, and operational updates for the specified period. It is a comprehensive report rather than a short announcement, fitting the definition of an Interim/Quarterly Report (IR). Q3 2021
2021-10-26 English
Xspray Pharma brings forward publication of the Q3 interim report
Report Publication Announcement Classification · 99% confidence The document explicitly states that Xspray Pharma is 'bringing forward the publication of its interim report for January-September, 2021'. The text is very short (2292 characters) and its primary function is to announce a change in the release date of a future report (the Q3 interim report). This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than being the comprehensive report itself (which would be classified as IR).
2021-10-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.